For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system exceeded safety and performance goals, according to results of the ALIGN-AR ...

Real-world data showed that low-risk patients who underwent transcatheter aortic valve replacement (TAVR) had 1-year ...

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions ...

Heatwaves strain the cardiovascular system, increasing heart rate. This can be dangerous for those with pre-existing heart ...

Pitted against more established balloon-expandable Sapien 3 valves in TAVR for severe aortic stenosis, the Myval devices ...

The message that Ainnova’s CEO, Vinicio Vargas, continues to convey to audiences around the world is that this accessible, fast, and scalable solution is designed to support early intervention and ...

Medtronic has reported late-breaking data from the Evolut Low Risk Trial’s five-year outcomes of the Evolut TAVR system.

BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of ...

With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.

Q1 2025 Earnings Conference Call April 16, 2025 9:00 AM ETCompany ParticipantsMike Comilla - VP, IRRobert Ford - Chairman ...

Researchers found that at five years, patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke.

The replacement system is launching into markets already served by repair devices, namely Edwards’ Pascal and Abbott’s ...